tiprankstipranks
Trending News
More News >
USANA Health (USNA)
NYSE:USNA

USANA Health (USNA) AI Stock Analysis

Compare
166 Followers

Top Page

US

USANA Health

(NYSE:USNA)

Rating:72Outperform
Price Target:
$34.00
▲(6.65%Upside)
USANA Health's stock is buoyed by strong earnings growth and proactive strategic initiatives, as highlighted in the latest earnings call. While technical indicators show positive momentum, financial performance is stable but challenged by declining revenues and net margins. Valuation metrics suggest the stock is fairly priced, making it an attractive investment in the packaged foods sector.

USANA Health (USNA) vs. SPDR S&P 500 ETF (SPY)

USANA Health Business Overview & Revenue Model

Company DescriptionUSANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
How the Company Makes MoneyUSANA Health Sciences generates revenue primarily through the sale of its nutritional supplements and personal care products, which are distributed via a direct selling model. This approach involves independent distributors, often referred to as 'associates,' who purchase products at a discounted price and sell them at retail value. Additionally, associates can earn commissions by recruiting and building their own sales teams, which helps expand the company's market reach. The company's earnings are significantly influenced by its international presence, with key markets in Asia, North America, and other regions. Strategic partnerships and sponsorships, such as those with athletes and sports organizations, also play a role in enhancing brand visibility and credibility, contributing to revenue growth.

USANA Health Earnings Call Summary

Earnings Call Date:Apr 22, 2025
(Q1-2025)
|
% Change Since: 31.52%|
Next Earnings Date:Jul 29, 2025
Earnings Call Sentiment Positive
USANA's earnings call presented a strong start to fiscal year 2025 with significant growth in key markets and successful product launches. The acquisition of Hiya is performing well, contributing positively to sales. However, cautious consumer sentiment and uncertainty around trade policies pose potential challenges. Nonetheless, the proactive strategies in place provide confidence in navigating these uncertainties.
Q1-2025 Updates
Positive Updates
Strong Overall Start to Fiscal Year 2025
USANA reported a 12% year-over-year growth in consolidated net sales in constant currency, aligning with internal expectations. This includes the first full quarter contribution from Hiya.
Growth in Key Markets
Mainland China experienced a 6% growth in net sales and a 4% increase in active customers sequentially. South Korea also showed sequential growth in net sales and active customers.
Successful Product Launches
USANA expanded its product offerings in several markets, including new products in China, leading to higher-than-expected sales performances.
Hiya Acquisition Performance
Hiya showed strong growth in net sales and active monthly subscribers, with successful product launches such as Kids Daily Greens exceeding expectations.
Proactive Trade Strategy
USANA has built up inventory to mitigate potential tariff impacts and has explored alternative sourcing relationships to address emerging trade policies.
Negative Updates
Cautious Consumer Sentiment
Overall consumer sentiment remains cautious in key markets, posing potential challenges to sustaining growth.
Uncertainty in Trade Policies
The impact of potential trade policies and tariffs remains uncertain, which could affect future financial results.
Slow Progress in India
Despite high expectations, growth in the Indian market has been slow and requires continued focus to gain momentum.
Company Guidance
During the call, USANA Health Sciences provided guidance for the fiscal year 2025, highlighting a positive start with consolidated net sales growing by 12% year-over-year in constant currency. The company observed sequential growth in net sales and active customers for the second consecutive quarter, with a notable 6% and 4% increase in their largest market, Mainland China. The newly acquired Hiya business also showed strong performance, with significant growth in net sales and active monthly subscribers. While USANA remains on track to meet its sales guidance, the potential impact of tariffs and trade policies remains uncertain. The company has proactively built inventory to mitigate tariff exposure and is exploring alternative sourcing relationships. Overall, USANA is optimistic about its growth trajectory, driven by product innovation and strategic initiatives.

USANA Health Financial Statement Overview

Summary
USANA Health demonstrates strong gross profit margins and a solid balance sheet characterized by low leverage and strong equity. However, the company faces challenges with declining revenues, reduced net profit margins, and lower free cash flow growth. The overall financial position remains stable, but the company needs to address revenue and net income declines for improved financial performance.
Income Statement
65
Positive
USANA Health has experienced a declining revenue trend over the last few years, with a revenue decrease of approximately 7% from 2023 to 2024. The gross profit margin in 2024 was strong at around 81%, indicating efficient cost management. However, net profit margin decreased to about 4.92% in 2024 compared to 6.92% in 2023, reflecting pressure on net income. Despite this, the company maintains a solid EBIT margin at 7.76% in 2024. Overall, the company shows strong gross margins but faces challenges with declining revenues and net profitability.
Balance Sheet
70
Positive
USANA Health's balance sheet reflects a strong equity position with an equity ratio of approximately 71.1% in 2024, indicating financial stability and low leverage. The debt-to-equity ratio remains low at 0.04, demonstrating conservative financial management and limited reliance on debt. Return on equity decreased to 7.9% in 2024 from 12.8% in 2023, indicating reduced profitability on equity investments. Overall, the company's balance sheet is robust, supported by strong equity and low debt levels, although ROE has seen a decline.
Cash Flow
60
Neutral
The cash flow analysis shows a modest decrease in free cash flow from 2023 to 2024 by about 9.3%. The operating cash flow to net income ratio is healthy, suggesting efficient cash generation relative to net income. However, the free cash flow to net income ratio has declined, reflecting less cash available after capital expenditures. Despite these challenges, USANA Health continues to generate positive operating cash flow. Overall, cash flows are positive, but there is a downward trend in free cash flow growth.
BreakdownTTMDec 2024Dec 2023Dec 2022Mar 2022Mar 2021
Income Statement
Total Revenue876.24M854.50M921.01M998.60M1.19B1.13B
Gross Profit705.65M693.29M744.32M804.71M968.57M925.53M
EBITDA91.59M98.86M123.11M130.22M192.89M200.96M
Net Income34.92M42.03M63.79M69.35M116.50M124.66M
Balance Sheet
Total Assets632.76M748.19M632.76M596.55M577.74M640.89M
Cash, Cash Equivalents and Short-Term Investments330.42M181.77M330.42M288.42M239.83M311.92M
Total Debt13.21M29.01M13.21M6.89M7.08M8.62M
Total Liabilities135.56M161.86M135.56M162.08M182.62M199.24M
Stockholders Equity497.20M532.11M497.20M434.47M395.12M441.65M
Cash Flow
Free Cash Flow49.12M50.92M56.15M93.50M108.46M145.31M
Operating Cash Flow58.79M60.99M70.64M103.90M121.23M160.40M
Investing Cash Flow-212.90M-213.09M-11.97M-12.37M-14.19M-33.96M
Financing Cash Flow7.03M9.55M-14.24M-30.09M-181.41M-59.44M

USANA Health Technical Analysis

Technical Analysis Sentiment
Positive
Last Price31.88
Price Trends
50DMA
29.35
Positive
100DMA
29.08
Positive
200DMA
32.92
Negative
Market Momentum
MACD
0.50
Negative
RSI
63.60
Neutral
STOCH
71.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For USNA, the sentiment is Positive. The current price of 31.88 is above the 20-day moving average (MA) of 30.33, above the 50-day MA of 29.35, and below the 200-day MA of 32.92, indicating a neutral trend. The MACD of 0.50 indicates Negative momentum. The RSI at 63.60 is Neutral, neither overbought nor oversold. The STOCH value of 71.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for USNA.

USANA Health Risk Analysis

USANA Health disclosed 41 risk factors in its most recent earnings report. USANA Health reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

USANA Health Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$274.18M27.756.42%2.00%-37.09%
72
Outperform
$579.74M16.726.78%-2.69%-43.24%
HLHLF
71
Outperform
$942.08M3.37-31.74%-2.45%100.59%
71
Outperform
$168.56M19.1830.11%1.38%8.22%159.71%
63
Neutral
$689.97M-5.95%2.44%91.41%
51
Neutral
$7.55B0.39-61.90%2.32%17.14%1.55%
44
Neutral
$134.48M-31.83%-8.50%-186.18%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
USNA
USANA Health
31.88
-13.09
-29.11%
HLF
Herbalife
9.25
-2.11
-18.57%
NATR
Nature's Sunshine Products
14.85
-0.15
-1.00%
STKL
SunOpta
6.00
0.68
12.78%
HAIN
Hain Celestial
1.66
-5.32
-76.22%
LFVN
LifeVantage
13.39
7.48
126.57%

USANA Health Corporate Events

Executive/Board ChangesShareholder Meetings
USANA Health Holds Annual Shareholders Meeting
Neutral
May 20, 2025

On May 19, 2025, USANA Health conducted its Annual Meeting of Shareholders, where approximately 92% of the company’s shares were represented. During the meeting, shareholders elected eight individuals to the Board of Directors, approved the 2025 Equity Incentive Plan, ratified KPMG LLP as the independent accounting firm for fiscal year 2025, and approved executive compensation on an advisory basis.

The most recent analyst rating on (USNA) stock is a Hold with a $65.00 price target. To see the full list of analyst forecasts on USANA Health stock, see the USNA Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
USANA Health Reports Q1 2025 Financial Results
Neutral
Apr 22, 2025

USANA Health Sciences reported its financial results for the first quarter of 2025, showing a 10% increase in net sales compared to the same period in 2024, despite a decline in net earnings and diluted EPS. The company reiterated its full-year outlook, highlighting strong growth in its Hiya direct-to-consumer business and a modest increase in direct sales and active customers. USANA is confident in its growth trajectory, despite global economic uncertainties, and continues to manage its supply chain effectively to mitigate potential impacts from trade policies and tariffs.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 17, 2025